共 50 条
- [21] Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Aggarwal, CharuDahlberg, Suzanne EleanorHanna, NasserKolesar, JillHirsch, Fred R.Ramalingam, Suresh S.Schiller, Joan H.
- [22] Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancerJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Shipley, D.Spigel, D. R.Burris, H. A., IIIWaterhouse, D. M.Webb, C. D.Gian, V.Hart, L. L.Greco, F. A.Hainsworth, J. D.
- [23] Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trialJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Garon, E. B.Kabbinavar, F. F.Neidhart, J. A.Neidhart, J. D.Gabrail, N. Y.Oliveira, M. R.Lu, S. P.Balkissoon, J.
- [24] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial-E4599JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090SSandler, ABGray, RBrahmer, JDowlati, ASchiller, JHPerry, MCJohnson, DH
- [25] Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599LUNG CANCER, 2005, 49 : S31 - S31Sandler, ABGray, RBrahmer, JDowlati, ASchiller, JHPerry, MCJohnson, DH
- [26] A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S795 - S795Herbst, RoyRedman, MaryKim, Edward S.Semrad, Thomas J.Bazhenova, LyudmilaMasters, GregoryOettel, KurtGuaglianone, PerryReynolds, ChristopherKarnad, AnandArnold, Susanne M.Varella-Garcia, MarileilaMoon, JamesMack, Philip C.Blanke, Charles D.Hirsch, Fred R.Gandara, David R.
- [27] Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung CancerCANCER RESEARCH AND TREATMENT, 2011, 43 (01): : 19 - 23Kim, Han JoKim, Kyoung HaYun, JinaKim, Se HyungKim, Hyun JungLee, Sang-CheolBae, Sang ByungKim, Chan KyuLee, Nam SuLee, Kyu TaekKim, Do-JinPark, Seong-KyuWon, Jong-HoHong, Dae SikPark, Hee Sook
- [28] Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Semrad, Thomas JohnRedman, Mary WeberHerbst, Roy S.Kim, Edward S.Bazhenova, LyudmilaMasters, Gregory A.Oettel, Kurt R.Guaglianone, PerryReynolds, Christopher M.Karnad, Anand B.Arnold, Susanne M.Varella-Garcia, MarileilaMoon, JamesMack, Philip C.Blanke, Charles DavidHirsch, Fred R.Kelly, KarenGandara, David R.
- [29] Meloxicam (M) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649STakahashi, TKogure, YUeda, SEbisawa, MAsai, GYamamoto, N
- [30] Motesanib or bevacizumab in combination with paclitaxel and carboplatin in patients with advanced nonsquamous non-small cell lung cancer (NSCLC): interim results from a randomized, open-label, phase 2 studyEJC SUPPLEMENTS, 2009, 7 (02): : 555 - 555Blumenschein, G., Jr.Schwartzberg, L. S.Menon, H.Mok, T. S. K.Stephenson, J. J.Beck, J. T.Lakshmaiah, K.Kracht, K.Sikorski, R.Kabbinavar, F.